Swiss National Bank Has $65.30 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Swiss National Bank trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 3.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 475,500 shares of the life sciences company’s stock after selling 19,500 shares during the quarter. Swiss National Bank owned approximately 0.30% of Illumina worth $65,296,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Illumina by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 18,178,513 shares of the life sciences company’s stock worth $2,531,176,000 after acquiring an additional 210,755 shares during the last quarter. Edgewood Management LLC grew its stake in Illumina by 4.6% in the 4th quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock valued at $957,762,000 after buying an additional 302,222 shares during the last quarter. Baillie Gifford & Co. grew its position in shares of Illumina by 8.7% in the first quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock valued at $787,725,000 after purchasing an additional 460,649 shares during the last quarter. WCM Investment Management LLC increased its position in Illumina by 2,232.3% during the 1st quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock worth $463,760,000 after buying an additional 3,232,418 shares during the period. Finally, Capital World Investors bought a new stake in shares of Illumina in the fourth quarter valued at about $271,753,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 1.6 %

Shares of NASDAQ:ILMN traded down $1.91 during mid-day trading on Friday, hitting $116.09. 1,612,071 shares of the company traded hands, compared to its average volume of 3,827,003. The stock has a 50-day moving average price of $108.95 and a two-hundred day moving average price of $125.50. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $195.64. The stock has a market cap of $18.49 billion, a P/E ratio of -14.24 and a beta of 1.15. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the firm earned $0.08 EPS. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. On average, equities research analysts forecast that Illumina, Inc. will post 0.98 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Illumina in a report on Monday, June 3rd. They issued a “hold” rating and a $115.00 price objective for the company. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Evercore ISI reduced their price objective on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 11th. Finally, StockNews.com initiated coverage on shares of Illumina in a research report on Sunday, June 30th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $158.57.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.